Demographic data
| SOF LED | SOF DACLA | P value | ||
| N=51 | N=77 | |||
| Age | Range | 33–66 | 36–69 | 0.077 |
| Mean±SD | 53.1±8.3 | 50.6±7.8 | ||
| Sex | Male | 30 (58.8%) | 42 (54.5%) | 0.633 |
| Female | 21 (41.2%) | 35 (45.5%) | ||
| Body mass index (BMI) | Range | 23–36 | 23–35 | 0.562 |
| Mean±SD | 29.9±2.8 | 28.6±2.6 | ||
| Residence | Rural | 26 (51%) | 39 (50.6%) | 0.971 |
| Urban | 25 (49%) | 38 (49.4%) | ||
| Comorbid diseases | No | 35 (68.6%) | 48 (62.3%) | 0.466 |
| Yes | 16 (31.4%) | 29 (37.7%) | ||
| Comorbid diseases | Hypertension | 3 (5.9%) | 5 (6.5%) | 0.961 |
| Diabetes | 7 (13.7%) | 11 (14.3%) | ||
| Hypertension and diabetes | 3 (5.9%) | 7 (9.1%) | ||
| History of gout | 3 (5.9%) | 6 (7.8%) | ||
| Free | 35 (68.6%) | 48 (62.3%) | ||
Independent samples t-test for parametric quantitative data between the two groups.
χ2 test (if less than 20% of cells have expected count <5) or Fisher exact test (if more than 20% of cells have expected count <5) for qualitative data between the two groups.
Significant level at p value <0.05.
DACLA, daclatsvir; LED, ledipasvir; SOF, sofosbuvir.